How we treat central venous access device-related upper extremity DVT

Jul 12, 2017 | posted by Kelsey Bennett | Article of the Week | No comments

ARTICLE: How we treat central venous access device-related upper extremity DVT AUTHORS: Anita Rajasekhar and Michael B. Streiff JOURNAL: Blood 2017 :blood-2016-08-693671; doi: https://doi.org/10.1182/blood-2016-08-693671 Abstract Central venous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring central venous access as part of their medical care. Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous(...)

Welcome Interns, Residents and Fellows

Jul 10, 2017 | posted by Kelsey Bennett | Education | No comments

We would like to extend a warm welcome to our 2017-2018 interns, residents and fellows. This group of the best and brightest has come from all over, and we are honored to have them as a part of our department. This year's class consists of: 22 Bayview interns 16 Bayview assistant residents 16 Bayview residents(...)

Grisham, Michell and Williams Win Staff Recognition Awards

Jul 7, 2017 | posted by Kelsey Bennett | Congratulations | No comments

Congratulations to Sara Grisham, Deborah Michell and Kim Williams who were selected to receive this quarter's Staff Recognition Awards based on their glowing nominations. Sara Grisham serves a dual role as administrative coordinator for the Division of Molecular Medicine as well as the Center for Epigenetics. While fairly new to the department, she has had a lasting impact on both(...)

Jul 6, 2017 | posted by Kelsey Bennett | Article of the Week | No comments

ARTICLE: Myeloproliferative Neoplasms AUTHORS: Jerry L. Spivak JOURNAL: N Engl J Med. 2017 Jun 1; 376:2168-2181. doi: 10.1056/NEJMra1406186 The myeloproliferative neoplasms — polycythemia vera, essential thrombocytosis, and primary myelofibrosis — are unique hematopoietic stem-cell disorders that share mutations that constitutively activate the physiologic signal-transduction pathways responsible for hematopoiesis. Consequently, these disorders engage in phenotypic mimicry(...)

Jul 5, 2017 | posted by Kelsey Bennett | Article of the Week | No comments

ARTICLE: Older Adults' Views and Communication Preferences About Cancer Screening Cessation AUTHORS: Nancy L. Schoenborn, Kimberley Lee, Craig E. Pollack, Karen Armacost, Sydney M. Dy, John F. P. Bridges, Qian-Li Xue, Antonio C. Wolff, Cynthia Boyd JOURNAL: JAMA Intern Med. 2017 Jun 12. doi: 10.1001/jamainternmed.2017.1778. [Epub ahead of print] Abstract IMPORTANCE: Older adults with limited life expectancy are frequently screened for cancer even though it exposes them to risks of screeningwith minimal benefit. Patient preferences may be an important contributor to continued screening. OBJECTIVE: To examine older adults' views on the(...)

Bumpus Named Senior Consulting Strategist for Academic and Research Diversity

Jul 3, 2017 | posted by Kelsey Bennett | Congratulations, Leadership | No comments

Namandje Bumpus, associate professor in the Division of Clinical Pharmacology, has decided to transition from her role as the associate dean for institutional and student equity, effective July 1. After this time, she will take on a new position, as senior consulting strategist for Academic and Research Diversity. In her new role, she will support(...)

Medicaid Opioid Epic Tip Sheets and FAQs

Jun 29, 2017 | posted by Kelsey Bennett | Patient Care | No comments

The new Maryland rule requiring prior authorizations for opioids goes into effect Saturday, July 1. Epic has updated to support this new workflow with a standard Opioid Agreement and the prior authorization forms for both Maryland Medicaid and Priority Partners. If you have a patient on another Medicaid MCO plan, you will need fill out the form(...)

Appel Named Associate Administrator for Ambulatory Operations and Access

Jun 29, 2017 | posted by Kelsey Bennett | Administration | No comments

Mary Jo Appel began as the Associate Administrator for Ambulatory Operations and Access on June 19. Mary Jo joins us from the Wilmer Eye Institute, where she served as the Assistant Administrator for the Wilmer practices on the East Baltimore campus since 2012. Prior to joining the Johns Hopkins family, she managed a private Ophthalmology(...)

Jun 29, 2017 | posted by Kelsey Bennett | Article of the Week | No comments

ARTICLE: Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes AUTHORS: Annika S. Axelsson, Emily Tubbs, Brig Mecham, Shaji Chacko, Hannah A. Nenonen, Yunzhao Tang, Jed W. Fahey, Jonathan M. J. Derry, Claes B. Wollheim, Nils Wierup, Morey W. Haymond, Stephen H. Friend, Hindrik Mulder and Anders H. Rosengren JOURNAL: Sci Transl Med. 2017 Jun 14;9(394). pii: eaah4477. doi: 10.1126/scitranslmed.aah4477. Abstract A potentially useful(...)

Jun 29, 2017 | posted by Kelsey Bennett | Vice Chair Contributors | No comments

There is a global cyberattack in progress. Early indications are that it’s a variant of Petya malware, described by the Internet Storm Center here. The current attack has already affected computers throughout the Heritage Valley Health System in Pennsylvania, as well as disrupting Merck’s computer network. This attack is similar in some ways to last(...)

Medicine Matters

About Kelsey Bennett

Posts by Kelsey Bennett:

How we treat central venous access device-related upper extremity DVT

Welcome Interns, Residents and Fellows

Grisham, Michell and Williams Win Staff Recognition Awards

Myeloproliferative Neoplasms

Older Adults’ Views and Communication Preferences About Cancer Screening Cessation

Bumpus Named Senior Consulting Strategist for Academic and Research Diversity

Medicaid Opioid Epic Tip Sheets and FAQs

Appel Named Associate Administrator for Ambulatory Operations and Access

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Global Cyberattack in Progress

Facebook	Twitter	YouTube

LinkedIn	Google+	Instagram

Sharecare	E-News	Podcast

Join Our Social Media Communities >